Therapeutic options for advanced basal cell carcinoma (BCC) have been transformed by the introduction of Hedgehog pathway inhibitors (HPIs) and the emergence of immunotherapy. Led by a multidisciplinary expert panel, this activity uniquely features an experienced patient sharing key insights from their treatment journey. The discussion focuses on the role and place of HPIs and PD-1 inhibitors in advanced BCC and provides professional guidance on managing class-specific toxicities, including immune-mediated adverse events.
Upon successful completion of this educational activity, participants should be better able to:
Director, Oncodermatology Program
Professor of Dermatology
Memorial Sloan Kettering Cancer Center
New York City, NY
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources
